Article
Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
BMJ open - 5 Jul 2023
Wang Xiaoyang, Huang Huang, Sun Yan, Zhu Zheng, Jiang Bin, Yang Li
Abstract excerpt
OBJECTIVES: In December 2018, China launched national volume-based procurement (NVBP) to negotiate drug prices with manufacturers. Gefitinib was one of the 25 pilot drugs, which is used for treatment of non-small cell lung cancer. Lung cancer is the most common type of cancer in China and targeted drugs like gefitinib have been proven to provide clinical benefits to patients. This study aims to explore the impact...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.